Elevated Ca 19-9 Levels in Patient with Cholecystitis

Yıl 2018, Cilt: 40 Sayı: 2, 75 - 77, 01.05.2018

Bartu Badak Mustafa Salış

https://doi.org/10.20515/otd.340155

Öz

Abstract: Although CA 19-9 is a tumour marker, high levels of CA
19-9 have also been reported in benign conditions such as acute cholangitis,
cholecystitis or pancreatitis. We present here a 72 -year-old man with
complicated cholecystitis due to gallstone and elevated serum CA19-9 levels.
After cholecystectomy procedure CA19-9 level returned to normal. The level of
CA 19-9 should never be regarded as a gold standard but rather as a helpful
indicator when searching pancreatic and biliary malignancies.

Anahtar Kelimeler

cholecystitis, acute

Kolesistitli Bir Olguda Yüksek CA 19-9 Seviyesi

Öz

Öz: CA 19-9
bir tümör belirleyicisi olarak kullanılmasına rağmen akut kolanjit, kolesistit
ve pankreatit gibi benign durumlarda da yüksek düzeyleri bildirilmiştir. Bu
vakada 72 yaşında safra taşına bağlı komplike olmuş bir kolesistit ile birlikte
yükselmiş CA 19-9 düzeyine sahip bir hastamızı sunuyoruz. CA 19-9 düzeyi
kolesistektomi sonrasında normale döndü. CA 19-9 düzeyi altın standart bir test
olmamakla birlikte, pankreas ve safra kesesi malignitelerini araştırmada
yardımcı bir test olarak kabul edilmelidir.

Anahtar Kelimeler

kolesistit, akut

Kaynakça

• 1. Minato H, Nakanuma Y, Teroda Y. Expression of blood grouprelated antigens in cholangiocarcinoma in relation to nonneoplastic bile ducts. Histopathology 1996; 28: 411-419.
• 2. Akdogan M, Sasmaz N, Kayhan B, et al. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori 2001; 87: 337-339.
• 3. Maestranzi S, Premioslo R, Mitchell H, et al. The effect of benign and malignant liver disease on the tumor markers CA 19-9 and CEA. Ann Clin Biochem 1998; 35: 99-103.
• 4. Jalanka H, Kuusela P, Roberts P, et al. Comparison of a new tumor marker, CA 19-9, with alpha fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseaes. J Clin Pathol 1984; 37: 218-222.
• 5. Morris-Stiff G, Teli M, Jardine N, Puntis MC. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary Pancreat Dis Int 2009; 8: 620-6
• 6. Tolliver BA, O'Brien BL. Elevated tumor-associated antigen CA19-9 in a patient with an enlarged pancreas: does it always imply malignancy? Southern Med J 1997; 90: 89-90.
• 7. Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using receiver operating characteristic curve. Am J Gastroenterol 1999; 94: 1941-6.
• 8. Murohisa T, Sugaya H, Tetsuka I, Suzuki T, Harada T. A case of common bile duct stone with cholangitis presenting an extraordinary high serum CA 19-9 value. Int Med 1992; 31: 516-20
• 9. Marcouizos G, Ignatiadou E, Papanikolaou GE, Ziogas D, Fatouros M. Highly elevated serum levels of CA 19-9 in choledocholithiasis: a case report. Cases J 2009; 2: 6662.